Developments in intravesical therapy for non-muscle-invasive bladder cancer

References

• Wu X, Ros MM, Gu J, Kiemeney L. Epidemiology and genetic susceptibility to bladder cancer. BJU Int.102(9 Pt B), 1207–1215 (2008).
   PubMed Web of Science ®Google Scholar
• Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J. Clin.55(2), 74–108 (2005).
   PubMed Web of Science ®Google Scholar
• Zeegers MP, Tan FE, Dorant E, van Den Brandt PA. The impact of characteristics of cigarette smoking on urinary tract cancer risk: a meta-analysis of epidemiologic studies. Cancer89(3), 630–639 (2000).
   PubMed Web of Science ®Google Scholar
• Pelucchi C, Bosetti C, Negri E, Malvezzi M, La Vecchia C. Mechanisms of disease: the epidemiology of bladder cancer. Nat. Clin. Pract. Urol.3(6), 327–340 (2006).
   PubMedGoogle Scholar
• Messing EM. Urothelial tumors of the bladder. In: Campbell-Walsh Urology (9th Edition).Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA (Eds). Saunders Elsevier, PA, USA 2419–2431 (2007).
   Google Scholar
• Bastacky S, Ibrahim S, Wilczynski SP, Murphy WM. The accuracy of urinary cytology in daily practice. Cancer87(3), 118–128 (1999).
   PubMed Web of Science ®Google Scholar
• Têtu B. Diagnosis of urothelial carcinoma from urine. Mod. Pathol.22(Suppl. 2), S53–S59 (2009).
   PubMed Web of Science ®Google Scholar
• van Rhijn BW, van der Poel HG, van der Kwast TH. Urine markers for bladder cancer surveillance: a systematic review. Eur. Urol.47(6), 736–748 (2005).
   PubMed Web of Science ®Google Scholar
• Lokeshwar VB, Habuchi T, Grossman HB et al. Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers. Urology66(6 Suppl. 1), 35–63 (2005).
   PubMed Web of Science ®Google Scholar
• Bryan RT, Zeegers MP, James ND, Wallace DM, Cheng KK. Biomarkers in bladder cancer. BJU Int.105(5), 608–613 (2010).
   PubMedGoogle Scholar
• Epstein JI, Amin MB, Reuter VR, Mostofi FK. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am. J. Surg. Pathol.22(12), 1435–1448 (1998).
   PubMed Web of Science ®Google Scholar
• Sauter G, Algaba F, Amin MB et al. Tumours of the urinary system: non-invasive urothelial neoplasias. In: WHO Classification of Tumors of the Urinary System and Male Genital Organs.Eble JN, Sauter G, Epstein JI, Sesterhenn IA (Eds). IARC Press, Lyon, France, 29–34 (2004).
   Google Scholar
• Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Bohle A, Palou-Redorta J. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur. Urol.54(2), 303–314 (2008).
   PubMed Web of Science ®Google Scholar
• Hall MC, Chang SS, Dalbagni G et al. Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J. Urol.178(6), 2314–2330 (2007).
   PubMed Web of Science ®Google Scholar
• Histological typing of urinary bladder tumours. In: International Classification of Tumors No. 10. Mostofi FK, Sobin LH, Torloni H (Eds). WHO, Geneva, Switzerland, 21–22 (1973).
   Google Scholar
• Greene FL, Page DL, Flemming ID. Bladder cancer. In: American Joint Committee on Cancer Staging Manual.Greene FL, Page DL, Flemming ID (Eds). Springer, NY, USA 335–340 (2002).
   Google Scholar
• Sobin LH, Gospodariwicz M, Wittekind C. Urinary Bladder. In: TNM Classification of Malignant Tumors. UICC Union International Contre le Cancer.Sobin LH, Gospodariwicz M, Wittekind C (Eds). Wiley-Blackwell, NJ, USA 262–265 (2009).
   Google Scholar
• Kirkali Z, Chan T, Manoharan M et al. Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology66(6 Suppl. 1), 4–34 (2005).
   PubMed Web of Science ®Google Scholar
• Sylvester RJ, van der Meijden AP, Oosterlinck W et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur. Urol.49(3), 466–465 (2006).
   PubMed Web of Science ®Google Scholar
• Fernandez-Gomez J, Solsona E, Unda M et al. Prognostic factors in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette–Guérin: multivariate analysis of data from four randomized CUETO trials. Eur. Urol.53(5), 992–1001 (2008).
   PubMed Web of Science ®Google Scholar
• Fernandez-Gomez J, Madero R, Solsona E et al. Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette–Guérin: the CUETO scoring model. J. Urol.182(5), 2195–2203 (2009).
   PubMed Web of Science ®Google Scholar
• Brausi M, Collette L, Kurth K et al. Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies. Eur. Urol.41(5), 523–531 (2002).
   PubMed Web of Science ®Google Scholar
• Schwaibold HE, Sivalingam S, May F, Hartung R. The value of a second transurethral resection for T1 bladder cancer. BJU Int.97(6), 1199–1201 (2006).
   PubMed Web of Science ®Google Scholar
• Schulze M, Stotz N, Rassweiler J. Retrospective analysis of transurethral resection, second-look resection, and long-term chemo-metaphylaxis for superficial bladder cancer: indications and efficacy of a differentiated approach. J. Endourol.21(12), 1533–1541 (2007).
   PubMed Web of Science ®Google Scholar
• Guevara A, Salomon L, Allory Y et al. The role of tumor-free status in repeat resection before intravesical bacillus Calmette–Guérin for high grade Ta, T1 and CIS bladder cancer. J. Urol.183(6), 2161–2164 (2010).
   PubMed Web of Science ®Google Scholar
• Shaw GL, Bunce CJ. Fluorescence cystoscopy – how to do it. Photodiagnosis Photodyn. Ther.5(4), 267–270 (2008).
   Google Scholar
• Witjes JA, Redorta JP, Jacqmin D et al. Hexaminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: review of the evidence and recommendations. Eur. Urol.57(4), 607–614 (2010).
   PubMed Web of Science ®Google Scholar
• Sievert KD, Kruck S. Hexyl aminolevulinate fluorescence cystoscopy in bladder cancer. Expert Rev. Anticancer Ther.9(8), 1055–1063 (2009).
   PubMed Web of Science ®Google Scholar
• Filbeck T, Pichlmeier U, Knuechel R, Wieland WF, Roessler W. Do patients profit from 5-aminolevulinic acid-induced fluorescence diagnosis in transurethral resection of bladder carcinoma? Urology60(6), 1025–1028 (2002).
   PubMed Web of Science ®Google Scholar
• Grossman HB, Gomella L, Fradet Y et al. A Phase III, multicenter comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of superficial papillary lesions in patients with bladder cancer. J. Urol.178(1), 62–67 (2007).
   PubMed Web of Science ®Google Scholar
• Fradet Y, Grossman HB, Gomella L et al. A comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of carcinoma in situin patients with bladder cancer: a Phase III, multicenter study. J. Urol.178(1), 68–73 (2007).
   PubMed Web of Science ®Google Scholar
• Kausch I, Sommerauer M, Montorsi F et al. Fluorescence diagnosis in patients with non-muscle invasive bladder cancer: results of a metaanalysis. Aktuelle Urol.41(3), 171–177 (2010).
   Google Scholar
• Babjuk M, Soukup V, Petrik R, Jirsa M, Dvoracek J. 5-aminolaevulinic acid-induced fluorescence cystoscopy during transurethral resection reduces the risk of recurrence in stage Ta/T1 bladder cancer. BJU Int.96(6), 798–802 (2005).
   PubMedGoogle Scholar
• Mostafid H, Bunce C. Improved detection and reduced early recurrence of non-muscle invasive bladder cancer using hexaminolaevulinate fluorescence cystoscopy: results of a multicentre prospective randomized study (PC B305). BJU Int.104(7), 889–890 (2009).
   PubMed Web of Science ®Google Scholar
• Stenzl A, Cowan NC, De Santis M et al. The updated EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur. Urol.55(4), 815–825 (2009).
   PubMed Web of Science ®Google Scholar
• Bryan RT, Billingham LJ, Wallace DM. Narrow-band imaging flexible cystoscopy in the detection of recurrent urothelial cancer of the bladder. BJU Int.101(6), 702–705 (2008).
   PubMed Web of Science ®Google Scholar
• Herr HW, Donat SM. A comparison of white-light cystoscopy and narrow-band imaging cystoscopy to detect bladder tumour recurrences. BJU Int.102(9), 1111–1114 (2008).
   PubMed Web of Science ®Google Scholar
• Cauberg EC, Kloen S, Visser M et al. Narrow band imaging cystoscopy improves the detection of non-muscle-invasive bladder cancer. Urology76(3), 658–663 (2010).
   PubMed Web of Science ®Google Scholar
• Jakse G, Algaba F, Malmstrom PU, Oosterlinck W. A second-look TUR in T1 transitional cell carcinoma: why? Eur. Urol.45(5), 539–546 (2004).
   PubMed Web of Science ®Google Scholar
• Sylvester RJ, Oosterlinck W, van der Meijden AP. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J. Urol.171(6 Pt 1), 2186–2190 (2004).
   PubMed Web of Science ®Google Scholar
• Oddens JR, van der Meijden AP, Sylvester R. One immediate postoperative instillation of chemotherapy in low risk Ta, T1 bladder cancer patients. Is it always safe? Eur. Urol.46(3), 336–338 (2004).
   PubMed Web of Science ®Google Scholar
• Kaasinen E, Rintala E, Hellstrom P et al. Factors explaining recurrence in patients undergoing chemoimmunotherapy regimens for frequently recurring superficial bladder carcinoma. Eur. Urol.42(2), 167–174 (2002).
   PubMed Web of Science ®Google Scholar
• Berrum-Svennung I, Granfors T, Jahnson S, Boman H, Holmang S. A single instillation of epirubicin after transurethral resection of bladder tumors prevents only small recurrences. J. Urol.179(1), 101–105 (2008).
   PubMed Web of Science ®Google Scholar
• Cai T, Nesi G, Tinacci G et al. Can early single dose instillation of epirubicin improve bacillus Calmette–Guérin efficacy in patients with nonmuscle invasive high risk bladder cancer? Results from a prospective, randomized, double-blind controlled study. J. Urol.180(1), 110–115 (2008).
   PubMed Web of Science ®Google Scholar
• Hendricksen K, Witjes WP, Idema JG et al. Comparison of three schedules of intravesical epirubicin in patients with non-muscle-invasive bladder cancer. Eur. Urol.53(5), 984–991 (2008).
   PubMed Web of Science ®Google Scholar
• Gudjonsson S, Adell L, Merdasa F et al. Should all patients with non-muscle-invasive bladder cancer receive early intravesical chemotherapy after transurethral resection? The results of a prospective randomised multicentre study. Eur. Urol.55(4), 773–780 (2009).
   PubMed Web of Science ®Google Scholar
• Koga H, Kuroiwa K, Yamaguchi A, Osada Y, Tsuneyoshi M, Naito S. A randomized controlled trial of short-term versus long-term prophylactic intravesical instillation chemotherapy for recurrence after transurethral resection of Ta/T1 transitional cell carcinoma of the bladder. J. Urol.171(1), 153–157 (2004).
   Web of Science ®Google Scholar
• Serretta V, Morgia G, Altieri V et al. A 1-year maintenance after early adjuvant intravesical chemotherapy has a limited efficacy in preventing recurrence of intermediate risk non-muscle-invasive bladder cancer. BJU Int.106(2), 212–217 (2010).
   PubMed Web of Science ®Google Scholar
• Sylvester RJ, Oosterlinck W, Witjes JA. The schedule and duration of intravesical chemotherapy in patients with non-muscle-invasive bladder cancer: a systematic review of the published results of randomized clinical trials. Eur. Urol.53(4), 709–719 (2008).
   PubMed Web of Science ®Google Scholar
• Böhle A, Brandau S. Immune mechanisms in bacillus Calmette–Guérin immunotherapy for superficial bladder cancer. J. Urol.170(3), 964–969 (2003).
   PubMed Web of Science ®Google Scholar
• Gontero P, Bohle A, Malmstrom PU et al. The role of bacillus Calmette–Guérin in the treatment of non-muscle-invasive bladder cancer. Eur. Urol.57(3), 410–429 (2010).
   PubMed Web of Science ®Google Scholar
• van der Meijden AP, Sylvester RJ, Oosterlinck W, Hoeltl W, Bono AV. Maintenance bacillus Calmette–Guérin for Ta T1 bladder tumors is not associated with increased toxicity: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial. Eur. Urol.44(4), 429–434 (2003).
   PubMed Web of Science ®Google Scholar
• Shelley MD, Court JB, Kynaston H, Wilt TJ, Fish R, Mason MD. Intravesical bacillus Calmette–Guérin in Ta and T1 bladder cancer (review). Cochrane Database Syst. Rev.4, CD001986 (2010).
   Google Scholar
• Shelley MD, Mason MD, Kynaston H. Intravesical therapy for superficial bladder cancer: a systematic review of randomised trials and meta-analyses. Cancer Treat. Rev.36(3), 195–205 (2010).
   PubMed Web of Science ®Google Scholar
• Sylvester RJ, Brausi MA, Kirkels WJ et al. Long-term efficacy results of EORTC Genito-Urinary Group randomized Phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette–Guérin, and bacillus Calmette–Guérin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder. Eur. Urol.57(5), 766–773 (2009).
   Google Scholar
• Malmström PU, Sylvester RJ, Crawford DE et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette–Guérin for non-muscle-invasive bladder cancer. Eur. Urol.56(2), 247–256 (2009).
   PubMed Web of Science ®Google Scholar
• Lamm DL, Blumenstein BA, Crissman JD et al. Maintenance bacillus Calmette–Guérin immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J. Urol.163(4), 1124–1129 (2000).
   PubMed Web of Science ®Google Scholar
• Mack D, Holtl W, Bassi P et al. The ablative effect of quarter dose bacillus Calmette–Guérin on a papillary marker lesion of the bladder. J. Urol.165(2), 401–403 (2001).
   Web of Science ®Google Scholar
• Martinez-Pineiro JA, Flores N, Isorna S et al. Long-term follow-up of a randomized prospective trial comparing a standard 81 mg dose of intravesical bacille Calmette–Guérin with a reduced dose of 27 mg in superficial bladder cancer. BJU Int.89(7), 671–680 (2002).
   PubMed Web of Science ®Google Scholar
• Yoneyama T, Ohyama C, Imai A et al. Low-dose instillation therapy with bacille Calmette–Guérin Tokyo 172 strain after transurethral resection: historical cohort study. Urology71(6), 1161–1165 (2008).
   Google Scholar
• Ojea A, Nogueira JL, Solsona E et al. A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose bacillus Calmette–Guérin (27 mg) versus very low-dose bacillus Calmette–Guérin (13.5 mg) versus mitomycin C. Eur. Urol.52(5), 1398–1406 (2007).
   PubMed Web of Science ®Google Scholar
• Colombel M, Saint F, Chopin D, Malavaud B, Nicolas L, Rischmann P. The effect of ofloxacin on bacillus Calmette–Guérin induced toxicity in patients with superficial bladder cancer: results of a randomized, prospective, double-blind, placebo controlled, multicenter study. J. Urol.176(3), 935–939 (2006).
   PubMed Web of Science ®Google Scholar
• Durek C, Rusch-Gerdes S, Jocham D, Bohle A. Sensitivity of BCG to modern antibiotics. Eur. Urol.37(Suppl. 1), 21–25 (2000).
   Google Scholar
• Laufer M, Ramalingam S, Schoenberg MP et al. Intravesical gemcitabine therapy for superficial transitional cell carcinoma of the bladder: a Phase I and pharmacokinetic study. J. Clin. Oncol.21(4), 697–703 (2003).
   PubMed Web of Science ®Google Scholar
• Mattioli F, Curotto A, Manfredi V et al. Intravesical gemcitabine in superficial bladder cancer: a Phase II safety, efficacy and pharmacokinetic study. Anticancer Res.25(3c), 2493–2496 (2005).
   PubMed Web of Science ®Google Scholar
• Serretta V, Galuffo A, Pavone C, Allegro R, Pavone-Macaluso M. Gemcitabine in intravesical treatment of Ta–T1 transitional cell carcinoma of bladder: Phase I–II study on marker lesions. Urology65(1), 65–69 (2005).
   PubMed Web of Science ®Google Scholar
• Witjes JA, van der Heijden AG, Vriesema JL, Peters GJ, Laan A, Schalken JA. Intravesical gemcitabine: a Phase 1 and pharmacokinetic study. Eur. Urol.45(2), 182–186 (2004).
   PubMed Web of Science ®Google Scholar
• Gontero P, Marini L, Frea B. Intravesical gemcitabine for superficial bladder cancer: rationale for a new treatment option. BJU Int.96(7), 970–976 (2005).
   Google Scholar
• Hendricksen K, Witjes JA. Intravesical gemcitabine: an update of clinical results. Curr. Opin. Urol.16(5), 361–366 (2006).
   Google Scholar
• Porena M, Del Zingaro M, Lazzeri M et al. Bacillus Calmette–Guérin versus gemcitabine for intravesical therapy in high-risk superficial bladder cancer: a randomised prospective study. Urol. Int.84(1), 23–27 (2010).
   PubMed Web of Science ®Google Scholar
• Addeo R, Caraglia M, Bellini S et al. Randomized Phase III trial on gemcitabine versus mytomicin in recurrent superficial bladder cancer: evaluation of efficacy and tolerance. J. Clin. Oncol.28(4), 543–548 (2010).
   PubMed Web of Science ®Google Scholar
• Walton MI, Smith PJ, Workman P. The role of NAD(P)H: quinone reductase (EC 1.6.99.2, DT-diaphorase) in the reductive bioactivation of the novel indoloquinone antitumor agent EO9. Cancer Commun.3(7), 199–206 (1991).
   PubMed Web of Science ®Google Scholar
• Jain A, Phillips RM, Scally AJ, Lenaz G, Beer M, Puri R. Response of multiple recurrent TaT1 bladder cancer to intravesical apaziquone (EO9): comparative analysis of tumor recurrence rates. Urology73(5), 1083–1086 (2009).
   PubMed Web of Science ®Google Scholar
• Hendricksen K, van der Heijden AG, Cornel EB et al. Two-year follow-up of the Phase II marker lesion study of intravesical apaziquone for patients with non-muscle invasive bladder cancer. World J. Urol.27(3), 337–342 (2009).
   PubMed Web of Science ®Google Scholar
• van der Heijden AG, Moonen PM, Cornel EB et al. Phase II marker lesion study with intravesical instillation of apaziquone for superficial bladder cancer: toxicity and marker response. J. Urol.176(4 Pt 1), 1349–1353 (2006).
   PubMed Web of Science ®Google Scholar
• Puri R, Palit V, Loadman PM et al. Phase I/II pilot study of intravesical apaziquone (EO9) for superficial bladder cancer. J. Urol.176(4 Pt 1), 1344–1348 (2006).
   PubMed Web of Science ®Google Scholar
• Schiff PB, Horwitz SB. Taxol stabilizes microtubules in mouse fibroblast cells. Proc. Natl Acad. Sci. USA77(3), 1561–1565 (1980).
   PubMed Web of Science ®Google Scholar
• McKiernan JM, Masson P, Murphy AM et al. Phase I trial of intravesical docetaxel in the management of superficial bladder cancer refractory to standard intravesical therapy. J. Clin. Oncol.24(19), 3075–3080 (2006).
   PubMed Web of Science ®Google Scholar
• Barlow L, McKiernan J, Sawczuk I, Benson M. A single-institution experience with induction and maintenance intravesical docetaxel in the management of non-muscle-invasive bladder cancer refractory to bacille Calmette–Guérin therapy. BJU Int.104(8), 1098–1102 (2009).
   PubMed Web of Science ®Google Scholar
• Laudano MA, Barlow LJ, Murphy AM et al. Long-term clinical outcomes of a Phase I trial of intravesical docetaxel in the management of non-muscle-invasive bladder cancer refractory to standard intravesical therapy. Urology75(1), 134–137 (2010).
   PubMed Web of Science ®Google Scholar
• Knemeyer I, Wientjes MG, Au JL. Cremophor reduces paclitaxel penetration into bladder wall during intravesical treatment. Cancer Chemother. Pharmacol.44(3), 241–248 (1999).
   PubMed Web of Science ®Google Scholar
• Rosato A, Banzato A, De Luca G et al. HYTAD1-p20: a new paclitaxel–hyaluronic acid hydrosoluble bioconjugate for treatment of superficial bladder cancer. Urol. Oncol.24(3), 207–215 (2006).
   PubMed Web of Science ®Google Scholar
• Le Visage C, Rioux-Leclercq N, Haller M, Breton P, Malavaud B, Leong K. Efficacy of paclitaxel released from bio-adhesive polymer microspheres on model superficial bladder cancer. J. Urol.171(3), 1324–1329 (2004).
   PubMed Web of Science ®Google Scholar
• Lu Z, Yeh TK, Tsai M, Au JL, Wientjes MG. Paclitaxel-loaded gelatin nanoparticles for intravesical bladder cancer therapy. Clin. Cancer Res.10(22), 7677–7684 (2004).
   PubMed Web of Science ®Google Scholar
• Mugabe C, Hadaschik BA, Kainthan RK et al. Paclitaxel incorporated in hydrophobically derivatized hyperbranched polyglycerols for intravesical bladder cancer therapy. BJU Int.103(7), 978–986 (2009).
   PubMed Web of Science ®Google Scholar
• Jimenez-Cruz JF, Vera-Donoso CD, Leiva O et al. Intravesical immunoprophylaxis in recurrent superficial bladder cancer (stage T1): multicenter trial comparing bacille Calmette–Guérin and interferon-a. Urology50(4), 529–535 (1997).
   PubMed Web of Science ®Google Scholar
• Joudi FN, Smith BJ, O’Donnell MA. Final results from a national multicenter Phase II trial of combination bacillus Calmette–Guérin plus interferon α-2B for reducing recurrence of superficial bladder cancer. Urol. Oncol.24(4), 344–348 (2006).
   PubMed Web of Science ®Google Scholar
• Harris JR, Markl J. Keyhole limpet hemocyanin (KLH): a biomedical review. Micron30(6), 597–623 (1999).
   PubMed Web of Science ®Google Scholar
• Jurincic CD, Engelmann U, Gasch J, Klippel KF. Immunotherapy in bladder cancer with keyhole-limpet hemocyanin: a randomized study. J. Urol.139(4), 723–726 (1988).
   PubMed Web of Science ®Google Scholar
• Jurincic-Winkler CD, Metz KA, Beuth J, Klippel KF. Keyhole limpet hemocyanin for carcinoma in situof the bladder: a long-term follow-up study. Eur. Urol.37(Suppl. 3), 45–49 (2000).
   PubMed Web of Science ®Google Scholar
• Lamm DL, Dehaven JI, Riggs DR. Keyhole limpet hemocyanin immunotherapy of bladder cancer: laboratory and clinical studies. Eur. Urol.37(Suppl. 3), 41–44 (2000).
   PubMed Web of Science ®Google Scholar
• Colombo R, Da Pozzo LF, Lev A, Freschi M, Gallus G, Rigatti P. Neoadjuvant combined microwave induced local hyperthermia and topical chemotherapy versus chemotherapy alone for superficial bladder cancer. J. Urol.155(4), 1227–1232 (1996).
   PubMed Web of Science ®Google Scholar
• Colombo R, Da Pozzo LF, Lev A et al. Local microwave hyperthermia and intravesical chemotherapy as bladder sparing treatment for select multifocal and unresectable superficial bladder tumors. J. Urol.159(3), 783–787 (1998).
   PubMed Web of Science ®Google Scholar
• Colombo R, Da Pozzo LF, Salonia A et al. Multicentric study comparing intravesical chemotherapy alone and with local microwave hyperthermia for prophylaxis of recurrence of superficial transitional cell carcinoma. J. Clin. Oncol.21(23), 4270–4276 (2003).
   PubMed Web of Science ®Google Scholar
• Gofrit ON, Shapiro A, Pode D et al. Combined local bladder hyperthermia and intravesical chemotherapy for the treatment of high-grade superficial bladder cancer. Urology63(3), 466–471 (2004).
   PubMed Web of Science ®Google Scholar
• van der Heijden AG, Kiemeney LA, Gofrit ON et al. Preliminary European results of local microwave hyperthermia and chemotherapy treatment in intermediate or high risk superficial transitional cell carcinoma of the bladder. Eur. Urol.46(1), 65–71 (2004).
   PubMed Web of Science ®Google Scholar
• Brausi M, Campo B, Pizzocaro G et al. Intravesical electromotive administration of drugs for treatment of superficial bladder cancer: a comparative Phase II study. Urology51(3), 506–509 (1998).
   PubMed Web of Science ®Google Scholar
• Di Stasi SM, Giannantoni A, Stephen RL et al. Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study. J. Urol.170(3), 777–782 (2003).
   PubMed Web of Science ®Google Scholar
• Di Stasi SM, Giannantoni A, Giurioli A et al. Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial. Lancet Oncol.7(1), 43–51 (2006).
   PubMed Web of Science ®Google Scholar
• Di Stasi SM, Storti L, Giurioli A. Single immediate preoperative instillation of electromotive mitomycin-C plus transurethral resection versus transurethral resection alone versus transurethral resection plus immediate mitomycin-C for pTa bladder tumors: long-term results of a prospective randomized trial. J. Urol.179(Suppl. 4), 585 (2008).
   Web of Science ®Google Scholar
• Schrier BP, Hollander MP, van Rhijn BW, Kiemeney LA, Witjes JA. Prognosis of muscle-invasive bladder cancer: difference between primary and progressive tumours and implications for therapy. Eur. Urol.45(3), 292–296 (2004).
   PubMed Web of Science ®Google Scholar
• Guzzo TJ, Magheli A, Bivalacqua TJ et al. Pathological upstaging during radical cystectomy is associated with worse recurrence-free survival in patients with bacillus Calmette–Guérin-refractory bladder cancer. Urology74(6), 1276–1280 (2009).
   PubMed Web of Science ®Google Scholar
• Nieder AM, Brausi M, Lamm D et al. Management of stage T1 tumors of the bladder: International Consensus Panel. Urology66(6 Suppl. 1), 108–125 (2005).
   PubMed Web of Science ®Google Scholar
• Witjes JA. Management of BCG failures in superficial bladder cancer: a review. Eur. Urol.49(5), 790–797 (2006).
   PubMed Web of Science ®Google Scholar
• Lamm DL, Colombel M, Persad R. Clinical practice recommendations for the management of non-muscle invasive bladder cancer. Eur. Urol. Suppl.7(10), 651–666 (2008).
   Google Scholar
• Steinberg G, Bahnson R, Brosman S, Middleton R, Wajsman Z, Wehle M. Efficacy and safety of valrubicin for the treatment of bacillus Calmette–Guérin refractory carcinoma in situ of the bladder. The Valrubicin Study Group. J. Urol.163(3), 761–767 (2000).
   PubMed Web of Science ®Google Scholar
• Dalbagni G, Russo P, Bochner B et al. Phase II trial of intravesical gemcitabine in bacille Calmette–Guérin-refractory transitional cell carcinoma of the bladder. J. Clin. Oncol.24(18), 2729–2734 (2006).
   PubMed Web of Science ®Google Scholar
• Mohanty NK, Nayak RL, Vasudeva P, Arora RP. Intravesical gemcitabine in management of BCG refractory superficial TCC of urinary bladder – our experience. Urol. Oncol.26(6), 616–619 (2008).
   PubMedGoogle Scholar
• Breyer BN, Whitson JM, Carroll PR, Konety BR. Sequential intravesical gemcitabine and mitomycin C chemotherapy regimen in patients with non-muscle invasive bladder cancer. Urol. Oncol.28(5), 510–514 (2009).
   Google Scholar
• Di Lorenzo G, Perdona S, Damiano R et al. Gemcitabine versus bacille Calmette–Guérin after initial bacille Calmette–Guérin failure in non-muscle-invasive bladder cancer: a multicenter prospective randomized trial. Cancer116(8), 1893–1900 (2010).
   PubMed Web of Science ®Google Scholar
• Barlow LJ, McKiernan JM, Benson MC. The novel use of intravesical docetaxel for the treatment of non-muscle invasive bladder cancer refractory to BCG therapy: a single institution experience. World J. Urol.27(3), 331–335 (2009).
   PubMed Web of Science ®Google Scholar
• O’Donnell MA, Krohn J, DeWolf WC. Salvage intravesical therapy with interferon-a 2b plus low dose bacillus Calmette–Guérin is effective in patients with superficial bladder cancer in whom bacillus Calmette–Guérin alone previously failed. J. Urol.166(4), 1300–1304 (2001).
   PubMed Web of Science ®Google Scholar
• O’Donnell MA, Lilli K, Leopold C. Interim results from a national multicenter Phase II trial of combination bacillus Calmette–Guérin plus interferon α-2b for superficial bladder cancer. J. Urol.172(3), 888–893 (2004).
   PubMed Web of Science ®Google Scholar
• Witjes JA, Hendricksen K, Gofrit ON, Risi O, Nativ O. Intravesical hyperthermia and mitomycin-C for (BCG-refractory) carcinoma in situ of the urinary bladder. Eur. Urol.(Suppl. 6), 60 (2007).
   Google Scholar
• Nativ O, Witjes JA, Hendricksen K et al. Combined thermo-chemotherapy for recurrent bladder cancer after bacillus Calmette–Guérin. J. Urol.182(4), 1313–1317 (2009).
   PubMed Web of Science ®Google Scholar
• Berger AP, Steiner H, Stenzl A, Akkad T, Bartsch G, Holtl L. Photodynamic therapy with intravesical instillation of 5-aminolevulinic acid for patients with recurrent superficial bladder cancer: a single-center study. Urology61(2), 338–341 (2003).
   PubMed Web of Science ®Google Scholar
• Pan H, Ma X, Chen J, Jiang H. PDT combined with intravesical BCG instillation would form an autovaccine for bladder cancer? Med. Hypotheses73(4), 559–560 (2009).
   Google Scholar
• Stein JP, Lieskovsky G, Cote R et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J. Clin. Oncol.19(3), 666–675 (2001).
   PubMed Web of Science ®Google Scholar
• Huguet J, Crego M, Sabate S, Salvador J, Palou J, Villavicencio H. Cystectomy in patients with high risk superficial bladder tumors who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor. Eur. Urol.48(1), 53–59 (2005).
   PubMed Web of Science ®Google Scholar
• Denzinger S, Fritsche HM, Otto W, Blana A, Wieland WF, Burger M. Early versus deferred cystectomy for initial high-risk pT1G3 urothelial carcinoma of the bladder: do risk factors define feasibility of bladder-sparing approach? Eur. Urol.53(1), 146–152 (2008).
   PubMed Web of Science ®Google Scholar
• Di Stasi SM, Riedl C. Updates in intravesical electromotive drug administration of mitomycin-C for non-muscle invasive bladder cancer. World J. Urol.27(3), 325–330 (2009).
   PubMed Web of Science ®Google Scholar